



15<sup>th</sup> Biennial Symposium  
of the International  
Society for Strategic  
Studies in Radiology

# IS3R 2023

Berlin/Germany  
August 24–26, 2023

# HOW CLOSE ARE COMPREHENSIVE AI SOLUTIONS?



***Jacob Sosna, MD***  
***Hadassah Hebrew University***  
***Medical Center***  
***Jerusalem, Israel***



# DISCLOSURES

- FUNDER HIGH-RAD

AI will replace **ALL** physicians

**#SARELGAURMD**





## PROF. GEOFFREY HINTON-2016



Geoffrey Hinton

"I think that if you work as a radiologist, you are like Wile E. Coyote in the cartoon. You're already over the edge of the cliff, but you haven't yet looked down. There's no ground underneath. People should stop training radiologists now. It's just completely obvious that in five years deep learning is going to do better than radiologists."

Nov 24, 2016



**SURVEILLANCE TECHNOLOGY**



# START-UP NATION

*Windows NT, XP  
developed  
primarily in Israel*



*Israeli lab reports successful transplant of  
lab-grown bones*




**Leading MS medication  
worldwide**





# START-UP MAP OF TEL AVIV



# Israel AI

cupHub.ai


## ISRAELI AI HEALTHCARE LANDSCAPE





# THE INFORMATION AGE

- USA:
  - X-RAY 250 M
  - CT 82 M
  - MRI 39 M



# Radiology and AI


## Trends and needs

- Increase in the clinical load: more than 40% in the last 5 years
  - Worldwide ~100M comparative studies
- Continued growth in the number of patients
- Shortage of radiologists
- Unprecedented pressure to find automatic solutions to support the radiologists

**→ Boost the need for AI solutions**

# Deep learning and race cars


*where's the catch?*





# RADIOLOGIST (HI) IN THE LOOP WORKFLOW

## BOOSTRAPPING RADIOLOGY



## Goals


- Provide useful results as soon as possible
- Optimize radiologist time budget
- Improve deep learning model
- Handle rare and out-of-distribution cases

# TYPES OF MACHINE LEARNING MODELS


## Supervised Learning



## Unsupervised Learning




## Reinforcement Learning



# AI in Radiology: overview and evidence

## Primary Market


- **211 AI-based companies with 591 FDA-cleared applications;** most of the products are a single-point solution for a single finding.
- 448 of the approved devices are within radiology and cardiology
  - **75% are in radiology/oncology: 391 devices**
  - **11% are in cardiology: 57 devices**
  - **3% are in hematology: 15 devices**
  - **3% are in neurology: 14 devices**





# AI for Radiology: overview and evidence




- Subspecialty: 32% in Neuroradiology, 27% are in Chest, 9% in breast, 9% in MSK (bone), 9% in multiple, 8% in Abdoman, and 7% in cardiac
- Modality: 33% in CT, 29% in MR, 19% in X-ray, 8% in mammography, 5% in ultrasound and 6% in others
- Main Functionality: 44% quantitative, 22% detection, 14% in Triage, 14% in Diagnostic and 4% in others



Shifting from single-point solutions to multiple-point solutions

# CE marked AI products for Radiology

Status as of February 22, 2023



# Value Proposition of Food and Drug Administration (FDA)- Approved Artificial Intelligence (AI) Algorithms for Neuroimaging JACR, August 11<sup>th</sup>, 2023

August 11, 2023 DOI: <https://doi.org/10.1016/j.jacr.2023.06.03>

- A total of 59 AI neuroimaging algorithms were cleared by the FDA between May 2008 and August 2022
- Most of these algorithms (24/59) were compatible with noncontrast CT, 21 with MRI, nine with CT perfusion, eight with CT angiography, three with MR perfusion, and two with PET
- Six algorithms were compatible with multiple imaging techniques.
- The following are the advertised value proposition for these algorithms:
  - Improved quality of care (38/55, 69.1%)
  - Saving user time (24/55, 43.6%)
  - Decreased costs (9/55, 15.7%)
  - Increased revenue (6/55, 10.9%)



# Value Proposition of Food and Drug Administration (FDA)- Approved Artificial Intelligence (AI) Algorithms for Neuroimaging JACR, August 11<sup>th</sup>, 2023

August 11, 2023 DOI: <https://doi.org/10.1016/j.jacr.2023.06.03>


## Take-Home Points:

1. A majority of the FDA- cleared AI algorithms approved for neuroimaging are related to the **detection or quantification of stroke**.
2. Most of the algorithms in this study focus on a **single clinical problem with binary outcome**.
3. The most widely advertised value proposition was **improved quality of care**.

# NARROW AI – LONG TIME AND HIGH COSTS!

Slide: K Dreyer

## AI USE CASES IN DIAGNOSTICS

Modality 

Specialty	COMPUTED TOMOGRAPHY	MAGNETIC RESONANCE	POSITRON EMISSION	RADIOGRAPHY	ANGIOGRAPHY	ULTRASOUND	FLUOROSCOPY	
ABDOMINAL IMAGING								FINDINGS
BREAST IMAGING						Tumors		FINDINGS
CARDIAC IMAGING								FINDINGS
EMERGENCY IMAGING				Pneumonia				FINDINGS
MUSCULOSKELETAL	Spine							FINDINGS
NEURORADIOLOGY								FINDINGS
NUCLEAR MEDICINE								FINDINGS
PEDIATRIC IMAGING								FINDINGS
THORACIC IMAGING								FINDINGS
INTERVENTIONAL								FINDINGS
	ANATOMY	ANATOMY	ANATOMY	ANATOMY	ANATOMY	ANATOMY	ANATOMY	

*Not cost-effective for the vast majority of common conditions!*

\* Transfer learning, one-shot image classification, GANs to date have shown limited effectiveness for medical image classification tasks

# 96 AI companies building the next generation of radiology tech

## Diagnostic imaging

### Multiple diseases



### Stroke



### Heart disease



### Brain health



### Dental



### Oncology



## Image enhancement



## Guided imaging



## Point-of-care radiology




## Radiology workflow automation





# The AI market

- The map of the current landscape of commercially available AI companies by market share




**The AI platforms hold the most significant market share**

# Supportive clinical publications

- 64% of the companies don't have supportive clinical publications.

## Evidence 100 AI products for radiology



## Restraints and Challenges

- The **FDA regulations** concerning AI products are **constantly changing**, i.e., “Moving Target.”
- The European Regulation for **CE & MDR** demands more **substantial clinical evidence** and focuses on real-world performance



# AI consolidator platforms

- Is consolidation of products a comprehensive solution?

## AI consolidator platforms

- Companies have been doing so by opening their AI platform to other companies and/or developing multiple applications, i.e., **offering a multi-finding solution**
- **27 AI consolidator platforms for AI:** Nuance, Blackford, SH, Incepto, Medica:, Sectra, Fufifilm, TCM, Philips, Siemens, AstraZeneca, CTS, DeepPC, etc.
- Companies also pushed to get **multiple FDA Clearances** to extend their offering. For example, GE has 42 devices cleared, Siemens 29, Canon 17, Aidoc 13, Philips 10, Zebra (acquired by Nanox Vision) 9, Quantib 7 and Viz.ai 6

# AI consolidator platforms (n=27)

AI Platform	PACS/RIS vendor	OEM	AI vendor	Other
<b>Blackford Platform</b> (Blackford Analysis [Bayer])	<b>AI Connect</b> (Wellbeing Software)	<b>Automation Platform</b> (Canon Medical Systems)	<b>Aidoc aiOS</b> (Aidoc)	<b>Change Healthcare Marketplace</b> (Change Healthcare)
<b>CARPL</b> (CARPL.AI)	<b>Intelerad AI Hub and Odyssey</b> (Intelerad)	<b>Digital marketplace, syngo.via</b> (Siemens Healthineers)	<b>Arterys</b> (Arterys [Tempus])	<b>Imaging AI Orchestrator/Marketplace</b> (IBM)
<b>deepcOS</b> (deepc)	<b>Medimsight AI marketplace</b> (Medimsight)	<b>Fujifilm REiLI</b> (Fujifilm)		<b>Softway Medical</b> (Softway Medical)
<b>FOLIO platform</b> (Incepto)	<b>RUBEE for AI</b> (Agfa Healthcare)	<b>GE Edison</b> (GE Healthcare)	<b>Postprocessing platform</b>	<b>Precision Imaging Network</b> (Nuance)
<b>Myrian</b> (Intrasense)	<b>Sectra Amplifier Store</b> (Sectra)	<b>Philips AI Manager</b> (Philips Healthcare)	<b>Alma Health Platform</b> (Alma Health Platform)	<b>Calantic Digital Solutions</b> (Bayer Pharmaceuticals)
<b>Private AI Hub</b> (Ferrum Health)	<b>Telepaxx</b> (TELEPAXX)		<b>Eureka Clinical AI</b> (TeraRecon)	
	<b>Visage AI Accelerator</b> (Visage Imaging)			



# AI consolidator platforms (n=27)

- **Blackford (Bayer) - 80 apps across 30 partner vendors**
  - **Arterys - 19 apps for radiology from 11 vendors**
  - **Incepto - 22 apps for radiology; offered by modality, department and organ**
  - **DeepPC- 35 apps from over 20 partners**
- **Medica;**
  - **Sectra;**
  - **Fufifilm;**
  - **TCM;**
  - **Philips;**
  - **Siemens;**
  - **AstraZeneca;**
  - **CTS;**
  - **SH;**
  - **Nuance;**



# AI consolidator platform at the ECR 2023



The AI platforms offer a variety of apps without a common ground or focus

# AI consolidator platforms

- Is consolidation of products a comprehensive solution?
- NO



# Merging and Acquisition

- Is M&A a comprehensive solution?

# M&A activity

## Acquisitions



### Aidence and Quantib acquired by RadNet

American diagnostic imaging services company RadNet acquired the Dutch AI vendors [Aidence](#) (lung CT) and [Quantib](#) (prostate, neuro). This should build upon RadNet's AI division which already includes breast AI after an earlier acquisition of DeepHealth. So far it seems like not much is going to change for current customers. This acquisition is not the first in the medical imaging AI field, and probably won't be the last.

**Blackford announces our  
acquisition by Bayer**

NEWS | August 11, 2021

## Nanox to acquire Zebra Medical Vision for \$200m

Nanox will leverage the team, innovative AI technology and Cloud expertise of Zebra-Med to develop a med-tech firm.



# Changing market segments

## Shift of focus

### MaxQ discontinues Accipio AI software as firm switches gears

By Erik L. Ridley, AuntMinnie.com staff writer

January 13, 2022 -- Artificial intelligence (AI) software developer MaxQ is switching gears, discontinuing its Accipio line of software for detection and triage of intracranial hemorrhage (ICH) and ending its involvement in the development of image analysis-based AI applications.

Founded in 2014, Enlitic continues to innovate the way artificial intelligence is utilized in healthcare, shifting focus from diagnostics to workflow. Partnerships with the Department of Defense, Konica Minolta, TMC (a Unilabs company), as well as some of the largest diagnostic reading groups in the world give momentum continuing into 2022 with the debut of Curie™, an enterprise platform that utilizes human, artificial, and real-world intelligence to create an evidence-based solution for healthcare information.

"This is the first time Lunit's AI has been officially integrated into an insurance underwriting process, and this proves that our solutions can also bring value to workflows outside of hospital settings," said Brandon Suh, CEO of Lunit. "We are excited to expand the reach of our AI-powered software and become the driving force of digital innovation in the global insurance market."



# Shifting to Pharmaceutical

## Shift of focus

- **contextflow partners with clinical data company Medexprim:** The partnership is specifically aimed at indicating treatment effectiveness and predict disease progression in non-small cell lung cancer. This collaboration highlights the growing trend of AI vendors, in this case [contextflow](#), expanding their reach into the pharmaceutical and clinical research industries, broadening their customer base.
- **VIDA moving to pharma:** VIDA announced a partnership with RAYUS Radiology, an American provider of advanced diagnostic and interventional radiology, to onboard more than 150 locations as clinical trial imaging sites. [VIDA](#) originally focused on patient care with their lung AI VIDA Insights. But with the launch of the VIDA Lung Intelligence services last May, their focus seems to have completely shifted to biomarker analysis for pharma. Together with Thirona and Quibim forming another type of AI-vendors.

# Merging and Acquisition

- Is M&A a comprehensive solution?
- NO

# THE GENERAL PARADIGM OF MACHINE LEARNING

Input Data Training of Model (e.g. decision tree/neural network) Application

Variables


Images

Text

Videos


Others

Machine Learning




or


Deep Learning



Classification



Regression





# What is a comprehensive solution?

EXAMINATION: CHEST (PA AND LAT)

INDICATION: \_\_\_ year old woman with ?pleural effusion // ?pleural effusion

TECHNIQUE: Chest PA and lateral


COMPARISON: \_\_\_

FINDINGS:

Cardiac size cannot be evaluated. Large left pleural effusion is new. Small right effusion is new. The upper lungs are clear. Right lower lobe opacities are better seen in prior CT. There is no pneumothorax. There are mild degenerative changes in the thoracic spine

IMPRESSION:

a Large left pleural effusion



- Clinical information
- Comparison
- PA+Lat
- Most of these do not exist in current products


Johnson, A.E.W., Pollard, T.J., Berkowitz, S.J. *et al.* MIMIC-CXR, a de-identified publicly available database of chest radiographs with free-text reports. *Sci Data* 6, 317 (2019).

# Comprehensive Solutions

- **Replicating radiologists knowledge process**
  - **Clinical data for understanding significance of findings**
  - **Multiple modalities**
  - **Multiple time points**
  - **Incorporating other studies (echocardiography, bronchoscopy)**
  - **Pathological and genetic data**
  - *AI for image reconstruction*

# RADIOLOGICAL LESIONS FOLLOW-UP


- Measure **lesion changes over time**
- **Relative change** between consecutive scans is what matters
- **Lesion change type:** existing, new, disappeared





# WORKFLOW INTEGRATION

- COURTESY PROF. ELI KONEN



Internet Explorer - מכתב / שחרור 2-08:26 30/08/2022

at least one signature has problems.

**Discharge Letter:**  
**Occupational therapy...**

המלצות:  
ביקורת מרפאת כף יד בעוד שבוע עם בדיקת מעבדה עדכנית כולל ספירה, כימיה, CRP  
ביקורת מרפאה ראומטולוגית בעוד שבוע ומעקב מעבדה ראומטולוגית שנלקחה באשפוז  
ריפוי בעיסוק בקהילה - הפעלת שורש כף יד ואצבעות  
בכל החמרה לרבות עליית חום והחמרה בתפקוד היד - לפנות למיון  
המשך טיפול קבוע ומעקב רופא מטפל

תרופות להמשך טיפול

שם התרופה	אופן מתן	מינון	תדירות	משך	יחידות לניפוק	אריזות לניפוק	מרשם הערות	✓
TRAMADOL OD 100mg (TraMADol HCL)	P.O	100 mg	1 X 1 ביום	1 שבועות				✓
ROKACET PLUS tab (CODEINE PHOSPHATE, PARACETAMOL [ACETAMINOPHEN], CODEINE+PARACETAMOL+CAFFEINE, CAFFEINE)	P.O	1 tab/cap	3 X 1 ביום	5 ימים				✓

שם הרופא הבכיר האחראי על השחרור

**A disturbing lesson:  
Our referring physicians  
don't check the PACS or  
RIS...**

# IMPLEMENTATION OF AI FOR CHEST XR IN ISRAEL


- ❖ Our main concern is the undetected nodules...
- ❖ Asked for excel of all detected “nodules”  **list of 17,000 accession numbers...**
- ❖ Help for IT  Exclusion criteria:

- Oncological Pts.  
- Active in recent year




(Oncology Pts. are marked in the EMR)

- Probability < 45%



- PET CT /Chest CT - in recent year
- >2 chest x-rays - in recent week (ICU)



(to exclude ICU Pts.)



# IMPLEMENTATION OF AI FOR CHEST XR IN ISRAEL

- ❖ Workflow integration!
- ❖ Real-time integration of AI with patient data from other hospital systems

PRO  
SUCCESS



- Oncological Pts.
  - Active in recent year
- Probability < 45%
- PET CT /Chest CT - in recent year
- >2 chest x-rays - in recent week (ICU)

👉 5-10 “new” / unknown suspected nodule / day

## Current state

- *The market is fragmented and with multiple low hanging fruit solutions*
- *AI platforms offer a variety of apps without a common ground or focus*
- *The AI market is currently shifting from point solutions to multi-findings solution*
- *Real comprehensive solutions are lacking*
- *The demand for quantitative imaging biomarkers information is on the rise*

AI will replace **ALL** physicians

**#SARELGAURMD**



NEAR FUTURE

RADIOLOGISTS USING AI WILL REPLACE  
RADIOLOGISTS NOT USING IT








HOPEFULLY WITHIN 10 YEARS

RADIOLOGISTS USING COMPREHENSIVE AI  
SOLUTIONS WILL REPLACE RADIOLOGISTS  
NOT USING IT



***Thank you***



15<sup>th</sup> Biennial Symposium  
of the International  
Society for Strategic  
Studies in Radiology

# IS3R 2023

Berlin/Germany  
August 24–26, 2023